The legal action centers on the period between November 25, 2025, and May 4, 2026. Plaintiffs allege that Embecta’s management repeatedly characterized its insulin pen needle portfolio as resilient, despite internal knowledge of substantial competitive share loss and retail market volume decline. These assurances reportedly continued even as the company faced mounting headwinds that were not disclosed to the public.

The discrepancy came to light on May 5, 2026, when Embecta reported a sharp revenue decline during its second-quarter fiscal results. The company subsequently reduced its full-year 2026 adjusted earnings per share guidance by 43% and slashed its quarterly dividend from $0.15 to $0.01 per share. Reed Kathrein, a partner at Hagens Berman, noted that the firm is examining whether management’s earlier positive statements were intentionally misleading given the later admission of market weakness. Investors have until August 17, 2026, to file for lead plaintiff status.